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Abstract
Although it is recommended to initiate postoperative chemotherapy for colon cancer within 8 weeks after surgery, the feasibility and
impact of initiating chemotherapy before discharge after surgical resection has not been investigated.
Patients with stage II–IV colon cancer who received postoperative chemotherapy were dichotomized into early (chemotherapy
initiation before discharge) and control (chemotherapy initiation after discharge) groups. Amultivariable logistic regression model was
used to determine factors associated with delayed chemotherapy, deﬁned as more than 6 or 8 weeks after surgery.
From January 2004 to December 2012, of 729 patients with stage II–IV colon adenocarcinoma, 555 patients (76.1%) underwent
postoperative chemotherapy. Of them, 181 (32.6%) patients were included in the early group. Time to initiation of chemotherapy was
signiﬁcantly shorter in the early group than in the control group (14.9 days vs 31.5 days, P< . 001). Multivariate analysis revealed that
tumor stage and chemotherapy initiation strategy (odds ratio 8.4; 95% conﬁdence interval, 1–66, P= .041) were independent
predictors of delayed initiation of chemotherapy at more than 8 weeks. There was no difference in the completion rate of planned
chemotherapy cycles between the 2 groups (P> .05).
The strategy of initiating chemotherapy before discharge after surgery is safe and feasible and might reduce the potential delay in
chemotherapy initiation in patients with colon cancer.
Abbreviations: ASA = American Society of Anesthesiologists, BMI = body mass index, CI = conﬁdence interval, LOH = length of
hospital stay, OR = odds ratio, OS = overall survival.
Keywords: chemotherapy, colon cancer, survival1. Introduction
Adjuvant chemotherapy after surgical resection could improve
survival outcomes, especially in patients with stage III colon
cancer. 5-ﬂuorouracil/leucovorin with oxaliplatin has been
recommended as a standard chemotherapy regimen.[1] Although
still under debate, adjuvant chemotherapy is recommended for
patients with stage II colon cancer with high-risk features such as
T4, poorly differentiation, perforation or obstruction, and an
insufﬁcient number of harvested lymph nodes.
Deciding when to initiate chemotherapy is dependent on the
patient’s condition, and the Eastern Cooperative OncologyEditor: YX Sun.
JK and S-WC contributed equally to this work as co-ﬁrst authors.
The authors have no conﬂicts of interest to disclose.
a Department of Surgery, Yonsei University College of Medicine, b Yonsei
University College of Medicine, Seoul, South Korea.
∗
Correspondence: Jeonghyun Kang, Department of Surgery, Gangnam
Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro,
Gangnam-gu, Seoul 06273 South Korea (e-mail: ravic@naver.com).
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-
ND), where it is permissible to download and share the work provided it is
properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
Medicine (2019) 98:18(e15371)
Received: 2 November 2018 / Received in ﬁnal form: 12 March 2019 /
Accepted: 29 March 2019
http://dx.doi.org/10.1097/MD.0000000000015371
1Group performance status scale is used as the main primary
indicator. Various factors are associated with a delay in the
initiation of chemotherapy.[2] It is well known that delaying the
initiation of adjuvant chemotherapy until more than 8 weeks
after surgery for colorectal cancer adversely affects overall
survival (OS).[3,4] Because of these results, many clinicians have
attempted to initiate postoperative chemotherapy as soon as
possible. However, there have been concerns that patients who
receive postoperative chemotherapy earlier may experience more
side effects due to insufﬁcient postoperative recovery.
In our center, we use 2 different strategies for initiating
chemotherapyaftercolorectal cancer surgery.Theﬁrst isadiscussion
between the physician and patient regarding the date of initiating
chemotherapy at the ﬁrst out-patient clinic visit after discharge. The
second is commencementof chemotherapyby thesurgicaloncologist
before discharge after surgery. However, to our knowledge, few
studies have examined the efﬁcacy or feasibility of initiating
chemotherapy before discharge for patients with colon cancer.[5]
Therefore, the aim of this study was to determine the feasibility
and impact of initiating chemotherapy earlier after colon cancer
surgery.2. Materials and methods
2.1. Patient selection
We identiﬁed 729 patients who were diagnosed with and
underwent surgery for stage II, III, or IV colon cancer between
January 2004 and December 2012. All patients included in this
study were pathologically conﬁrmed with colon cancer based on
Kang et al. Medicine (2019) 98:18 Medicinesurgically resected specimens. Patients who did not receive
postoperative chemotherapy (n=174) were excluded. A total of
555 patients were selected for this analysis. This study was based
on a retrospective review from a single institution and was
approved by the Gangnam Severance Hospital’s Institutional
Review Board (3-2017-0256). Informed consent was waived for
this retrospective study.2.2. Surgery and chemotherapy initiation
Every patient diagnosed with colon cancer underwent surgical
procedures including right hemicolectomy, transverse colectomy,
left colectomy, anterior resection, subtotal colectomy, and total
colectomy. Principles of surgical resection included complete
mesocolic excision or total mesorectal excision. Detailed surgical
procedures were described in our previous report.[6]
Chemotherapy regimens used in our hospital included oral 5FU,
intravenous 5FU/LV, FOLFOX (folinic acid, 5-ﬂuorouracil,
oxaliplatin), andFOLFIRI (folinic acid, 5-ﬂuorouracil, irinotecan).
Some patients received 5FU-based chemotherapy because oxali-
platin was not covered by the national insurance reimbursement
during the earlier periods of our study. Cetuximab or bevacizumab
was relatively recently added, especially for stage IV patients. The
chemotherapy agent for each patient was discussed between the
physician and patient with consideration of patient recovery status
and recommended guidelines for postoperative chemotherapy.
In our hospital, in most cases, chemotherapy after colorectal
cancer resection was administered by the attending surgical
oncologists. The decision of when to start chemotherapy was
based on the surgical oncologist’s assessment of ﬁtness to start
chemotherapy, and the ECOG performance status scale was used
as a major tool. Although multidisciplinary team (MDT) meeting
was available in our hospital, not all of the patients were
discussed as the MDT meeting mainly focused on stage IV
patients or patients with recurrent disease.2.3. Deﬁnition of “early group” and “delayed
chemotherapy”
During the study period, 2 different strategies were implemented
for initiating chemotherapy after surgery. In the ﬁrst, patients
were encouraged to be discharged as soon as possible when they
recovered sufﬁciently to consume a soft diet and the physicians
assessed the patients’ recovery status and discussed the date of
initiating chemotherapy in the out-patient clinic. In the second,
the surgical oncologist initiated chemotherapy before discharge
after surgery. In this study, patients were categorized into the
early group when they received chemotherapy before discharge
and the control group when they received chemotherapy after
discharge (Fig. 1). Although the decision of chemotherapy
initiating was dependent on the surgical oncologist’s preference,Figure 1. Deﬁnition of early chemotherapy initiation group (early group).
2the early chemotherapy initiation strategy was mainly driven by
speciﬁc surgical oncologists in our hospital.
We calculated the interval from the date of surgery to the date
of initiation of chemotherapy and deﬁned “delayed chemothera-
py” as patients for whom that interval was either >6 or >8
weeks. Univariate and multivariate analyses were performed to
identify the factors that contributed to the difference in time to
initiation of chemotherapy.
2.4. Measured outcomes
Demographic data including gender, age, body mass index
(BMI), cancer stage, and American Society of Anesthesiologists
(ASA) grade were collected. Clinicopathologic variables includ-
ing tumor location (proximal colon, distal colon, synchronous),
surgery time, estimated blood loss, and complications were
assessed. Follow-up-related outcomes included resumption of
soft diet (days), length of hospital stay (LOH) (days), time to
initiation of adjuvant chemotherapy (days), and survival time. As
most previous studies deﬁned LOH as the time gap from surgery
to the discharge date, the LOH in the “early group” comprised
the routine recovery time after surgery and additional days for
ﬁrst-line postoperative chemotherapy, while the LOH in the
“control group” included only recovery days.
Patients were also assessed separately as subgroups according
to the presence of complications during the recovery period.
Complete chemotherapy was deﬁned as completing the planned
cycles of chemotherapy. Incomplete chemotherapywas deﬁned as
discontinuing or changing the chemotherapy regimen for any
reason before completing the planned schedule.2.5. Statistical analysis
All statistical analyses were performed using IBM SPSS version
23.0 (IBM Corp, Armonk, NY) and R version 3.5.1 (R-project,
Institute for Statistics and Mathematics). Differences in clinico-
pathologic features between the early and control groups were
analyzed using the chi-square test or Fisher exact test for
categorical variables and using the Student t test or Mann–
Whitney U test for continuous variables. OS was deﬁned as the
time from the date of surgery to the date of death or last follow-
up. The Kaplan–Meier method was used for survival analysis. OS
was categorized by patients who received adjuvant chemotherapy
within 6 and after 6 weeks and patients who received adjuvant
chemotherapy before and after discharge. The log-rank test was
used to compare survival outcomes between the 2 groups.
Univariate and multivariate analyses were performed using
logistic regression analysis. A P value <.05 was considered to
indicate signiﬁcance.
3. Results
3.1. Patient demographics
Of the 555 patients who received adjuvant chemotherapy, 181
(32.6%) initiated treatment before discharge (early group) and
374 (67.4%) initiated treatment after discharge (control group).
Open, laparoscopic, and robotic surgeries were performed in 158
(87.3%), 20 (11%), and 3 (1.7%) of the 181 patients in the early
group and in 125 (33.4%), 196 (52.4%), and 53 (14.2%) of the
374 patients in the control group, respectively.
Although there was no difference in gender, BMI, ASA grade,
and tumor location between the 2 groups, there were some
Table 1
Comparison of patient demographics and perioperative outcomes
between the 2 groups.
Early group
(n=181)
Control group
(n=374)
P
N (%) N (%)
Gender Male 111 (61.3) 231 (61.8) .921
Female 70 (38.7) 143 (38.2)
Age, yr Mean (SD) 57.8 (11.7) 61.8 (10.7) <.001
BMI, kg/m2 Mean (SD) 23.3 (3.0) 23.2 (3.0) .548
Stage II 72 (39.8) 109 (29.1) .042
III 79 (43.6) 196 (52.4)
IV 30 (16.6) 69 (18.4)
ASA grade† I 47 (57.3) 185 (52.0) .286
∗
II 33 (40.2) 141 (39.6)
III 2 (2.4) 29 (8.1)
IV 0 (0) 1 (0.3)
Tumor location Proximal colon 67 (37) 125 (33.4) .627
∗
Distal colon 114 (63) 248 (66.3)
Synchronous 0 (0) 1 (0.3)
Operation method Open 158 (87.3) 125 (33.4) <.001
Laparoscopy 20 (11) 196 (52.4)
Robot 3 (1.7) 53 (14.2)
Operation time Mean (SD) 227.1 (103.2) 250.4 (119.5) .025
Blood loss, mL Mean (SD) 302.7 (446.9) 251 (396.4) .168
Complications 57 (31.5) 62 (16.6) <.001
Chemotherapy agent Oral‡ 15 (8.3) 85 (22.7) <.001
IV 166 (91.7) 289 (77.3)
Tumor location: Proximal: Cecum – Transverse colon; Distal: Descending colon – Rectosigmoid junction.
ASA=American Society of Anesthesiologists, BMI=body mass index, SD= standard deviation.
∗
Fisher exact test.
† 438 patients (78.9%) were available.
‡ Oral chemotherapy included Capecitabine and Doxiﬂuridine.
Table 2
Demographics of Stage IV patients between the 2 groups (N=99).
Early group
(n=30)
Control group
(n=69)
N (%) N (%) P
Metastasis site Liver 19 (63.3) 49 (71) .09
∗
Lung 0 6 (8.7)
Others 11 (36.7) 14 (20.3)
Combined resection
of metastasis site
Yes 23 (76.7) 57 (82.6) .580
No 7 (23.3) 12 (17.4)
Chemotherapy agent Oral† 0 3 (4.3) .55
∗
IV 30 (100) 66 (95.7)
∗
Fisher exact test.
† Oral chemotherapy included Capecitabine and Doxiﬂuridine.
Table 3
Postoperative recovery outcomes and time to initiation of adjuvant ch
groups.
Soft diet resumed, d Overall Mean (SD)
Complication group Mean (SD)
No complication group Mean (SD)
Length of hospital stay, d Overall Mean (SD)
Complication group Mean (SD)
No complication group Mean (SD)
Time to initiation of chemotherapy, d Overall Mean (SD)
Complication group Mean (SD)
No complication group Mean (SD)
SD= standard deviation.
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3signiﬁcant differences in group characteristics. The mean age was
signiﬁcantly lower in the early group than in the control group
(57.8 years in the early group vs 61.8 years in the control group,
P< .001). The proportion of patients with stage III was slightly
higher in the control group (P= .042). The surgery time was
shorter in the early group than in the control group (227minutes
in the early group vs 250minutes in the control group, P= .025).
The complication rate was higher in the early group than in the
control group (31.5% in the early group vs 16.6% in the control
group, P< .001). Oral chemotherapy was more frequently
administered in the control group (8.3% in the early group vs
22.7% in the control group, P< .001) (Table 1).
Detailed demographic characteristics of patients with stage IV
cancer are described in Table 2. All patients who were staged as
stage IV in our study underwent primary colon resection with or
without combined resection of the metastatic site. The distribu-
tion of metastasis sites did not differ between the 2 subgroups,
and the liver was the main metastatic site in both subgroups
(63.3% in the early group vs 71% in the control group, P= .09).
Combined resection of the metastatic site, so-called metastasec-
tomy, was performed in 76.7% of patients with stage IV cancer in
the early group and 82.6% of patients with stage IV cancer in the
control group, which did not differ between the 2 subgroups
(P= .580).3.2. Comparison of time to initiation of chemotherapy
Time to resumption of a soft diet was signiﬁcantly longer in the
early group than in the control group (9.2 days vs 5.2 days,
P< .001). This tendency was maintained when the analysis was
repeated according to complication and no-complication groups.
The LOH was signiﬁcantly longer in the early group than in the
control group (25.2 days vs 14 days, P< .001). The time to
initiation of chemotherapy was signiﬁcantly shorter in the early
group than in the control group (14.9 days vs 31.5 days,
P< .001). In subgroup analysis, time to initiation of chemother-
apywas signiﬁcantly shorter in the early group than in the control
group in both the complication and no-complication groups
(Table 3).3.3. Factors associated with delayed chemotherapy
Factors associated with delayed chemotherapy of more than 6 or
8 weeks are shown in Table 4. In univariate analysis, stage and
chemotherapy initiation strategy were identiﬁed as signiﬁcantemotherapy according to presence of complication between the 2
Early group (n=181) Control group (n=374)
N (%) N (%) P
9.2 (3.3) 5.2 (3.4) <.001
10.5 (4.5) 7.1 (5.5) <.001
8.6 (2.2) 4.9 (2.7) <.001
25.2 (8.3) 15 (8.3) <.001
29.8 (9.7) 22.3 (13.5) .001
23.1 (6.6) 13.6 (5.8) <.001
14.9 (6.2) 31.5 (17.9) <.001
18.1 (8.1) 40.7 (31.7) <.001
13.5 (4.4) 29.7 (13.0) <.001
Table 4
Factors associated with delayed chemotherapy according to the delayed time either 6 wk or 8 wk.
Delayed more than 8 weeks Delayed more than 6 weeks
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
N N (%) P OR (95% CI) P N (%) P OR (95% CI) P
Gender Male 342 9 (2.6) .654 24 (7) .314
Female 213 7 (3.3) 20 (9.4)
Age, y <65 345 8 (2.3) .309 25 (7.2) .446
≥65 210 8 (3.8) 19 (9)
BMI, kg/m2 <25 405 13 (3.2) .576
∗
37 (9.1) .084 1 .179
≥25 150 3 (2.0) 7 (4.7) 0.5 (0.2–1.3)
ASA grade I 232 9 (3.9) .459
∗
23 (9.9) .049 1 .584
II–IV 206 4 (1.9) 18 (8.7) 0.6 (0.3–1.3)
Unknown 117 3 (2.6) 3 (2.6) 0.8 (0.2–3.5)
Tumor location Proximal 192 8 (4.2) .218
∗
17 (8.9) .651
∗
Distal 362 8 (2.2) 27 (7.5)
Synchronous 1 0 (0) 0 (0)
Stage Stage II 181 4 (2.2) .033
∗
1 .05 11 (6.1) .013 1 .044
Stage III 275 5 (1.8) 0.7 (0.1–2.7) 18 (6.5) 0.9 (0.4–2.2)
Stage IV 99 7 (7.1) 2.9 (0.8–10.3) 15 (15.2) 2.5 (0.9–6.2)
Complications No 436 11 (2.5) .354
∗
1 .204 23 (5.3) <.001 1 <.001
Yes 119 5 (4.2) 2 (0.6–6.2) 21 (17.6) 6 (3–12.2)
Op method Open 283 10 (3.5) .703
∗
28 (9.9) .210
∗
Laparoscopy 216 5 (2.3) 14 (6.5)
Robot 56 1 (1.8) 2 (3.6)
Chemotherapy start Early group 181 1 (0.6) .022 1 .041 1 (0.6) <.001 1 <.001
Control group 374 15 (4.0) 8.4 (1–66) 43 (11.5) 36.1 (4.3–301.6)
Tumor location: Proximal: Cecum – Transverse colon; Distal: Descending colon – Rectosigmoid junction.
ASA=American Society of Anesthesiologists, BMI=body mass index, CI= conﬁdence interval, OR=odds ratio.
∗
Fisher exact test.
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Multivariate analysis revealed that stage and chemotherapy
initiation strategy (odds ratio [OR], 8.4; 95% conﬁdence interval
[CI], 1–66, P= .041) were independent predictors of delayed
initiation of chemotherapy for more than 8 weeks.
ASA grade, stage, complications, and chemotherapy initiation
strategy were associated with delayed chemotherapy for more
than 6 weeks in univariate analysis. Stage, postoperative
complications, and chemotherapy initiation strategy (OR,
36.1; 95% CI, 4.3–301.6, P< .001) were signiﬁcantly associated
with delayed initiation of chemotherapy for more than 6 weeks
(Table 4).Table 6
Characteristics of secondary cycle chemotherapy in the early3.4. Comparison of completion rate of planned
chemotherapy cycles between the 2 groups
There was no difference in the rate of completion of the planned
cycles between the 2 groups (72.9% in the early group vs 72.7%
in the control group, P= .321) (Table 5).Table 5
Comparison of completion rate of planned chemotherapy cycles
between the 2 groups.
Early group
(n=181)
Control
group (n=374)
N (%) N (%) P
Complete of planned cycles 132 (72.9) 272 (72.7) .321
Incomplete 35 (19.3) 60 (16)
Unknown 14 (7.7) 42 (11.2)
43.5. Characteristics of secondary cycle chemotherapy in
the early group
Most of the second cycles of chemotherapy in the early group
were performed at the scheduled time (96.1%). There were 4
delays (2.2%) due to liver abscess development after radio-
frequency ablation, poor oral intake, general weakness, and
surgical site infection detected after discharge. Three patients
(1.7%) did not undergo further chemotherapy because of patient
refusal (Table 6).3.6. OS according to chemotherapy initiation time or
chemotherapy initiation strategy
Figure 2 presents the Kaplan–Meier curve for OS in patients with
stage II–IV colon cancer who received adjuvant chemotherapygroup.
N (%)
Gap between ﬁrst and
secondary cycle
Median (range), d 22.5 (9–63)
Feasibility of second cycle
of chemotherapy
No delay after 1st cycle 174 (96.1)
Delay after 1st cycle 4 (2.2)
Termination after 1st cycle 3 (1.7)
Reason of delayed
chemotherapy after 1st cycle
Liver abscess after
radiofrequency ablation of liver
1
Poor oral intake after discharge 1
Surgical site infection 1
General weakness 1
Figure 2. Overall survival according to the time interval from surgery to the initiation of chemotherapy.
Kang et al. Medicine (2019) 98:18 www.md-journal.comwithin and after 6 weeks following surgery. Among patients
in all stages, the 5-year OS was signiﬁcantly better in patients
who initiated adjuvant chemotherapy within 6 weeks than
in patients who delayed chemotherapy until after 6 weeks (5-year
OS: 78.8% vs 60.9%, P< .001) (Fig. 2A). In subgroup analysis,
patients with delayed chemotherapy for >6 weeks had a
much worse prognosis of stage III colon cancer (82.8% vs
60%, P= .001) (Fig. 2C), although there was no difference
in OS between the stage II and IV groups (Fig. 2B and D).
Figure 3 shows the OS in patients who received adjuvant
chemotherapy before and after discharge. Early initiation of
postoperative chemotherapy was not associated with worse
OS for all stages.
4. Discussion
This study demonstrated that early chemotherapy initiation before
discharge could be performed safely without delaying the second
cycle of chemotherapy or deteriorating the completion of planned
chemotherapy cycles in patients with colon cancer who have
undergone surgical resection. Early chemotherapy initiationbefore
discharge may be one possible option to reduce the potential delay
in chemotherapy initiation in patients with colon cancer, although
this should be conﬁrmed in a further prospective study.
A recent meta-analysis demonstrated that increased age, single
marital status, low socioeconomic status, poor comorbidity
status, low tumor grade, prolonged length of stay, and
readmission are associated with chemotherapy delays in
colorectal cancer.[2] Laparoscopy or robotic surgery compared5with the open approach is known to be a predictor of earlier
initiation of adjuvant chemotherapy, and this is regarded as one
of the beneﬁts of minimally invasive surgery.[6,7] In addition,
systematic delay within or out of the hospital might be one of the
most signiﬁcant factors for chemotherapy delay. It has been
reported that delayed time to adjuvant chemotherapy is more
process-related than patient-related, with signiﬁcant prolonga-
tion of intervals such as referral and consultation.[8] Bayraktar
et al also reported that 30% of the delays in chemotherapy after
surgical resection of colon cancer are caused by the hospital
system, such as referrals or insurance identiﬁcation.[9] These
factors reﬂect the different medical environments in each country.
Thus, to reduce the time interval between surgery and
chemotherapy it is better to focus on correctable causes such
as reducing the readmission rate or length of stay, performing
laparoscopic surgeries, and eliminating the time gap caused by
systematic barriers. In our hospital, surgical oncologists are
mainly responsible for deciding chemotherapy initiation for
patients with colorectal cancer. Although the beneﬁt of surgical
oncologist-driven chemotherapy has not been investigated, the
surgeon can predict patient recovery in more detail because they
already know the patients’ condition with respect to ﬁtness to
initiate chemotherapy. In this regard, the surgical oncologist
might be more comfortable in deciding the initiation of early
chemotherapy. Initiation of chemotherapy before discharge
could potentially eliminate the time gap caused by systematic
delays.
Previous studies have demonstrated that postoperative com-
plications signiﬁcantly delay the time to initiation of adjuvant
Figure 3. Overall survival according to the early group and the control group.
Kang et al. Medicine (2019) 98:18 Medicinechemotherapy in patients with colon cancer.[9,10] Longer hospital
stay and delayed consumption of adequate nutrition in patients
with complications might cause delayed initiation of chemother-
apy. However, in our analysis, the presence of complications did
not affect the rate of delayed chemotherapy >8 weeks (2.5% in
the no-complication group vs 4.2% in the complication group,
P= .354). In contrast, when we deﬁned delayed chemotherapy as
commencement of chemotherapy later than 6 weeks, postopera-
tive complications were an independent predictor of delayed
chemotherapy. One reason for this discordance might be a type II
error related to the insufﬁcient sample size of patients with
delayed chemotherapy >8 weeks.
Most studies accept the deﬁnition of delayed chemotherapy as
>8 weeks (56 days). The reported proportion of patients who
receive delayed chemotherapy range from 26% to 54%.[8,11–13]
In contrast, our study showed a signiﬁcantly lower proportion of
patients in the delayed chemotherapy group (2.9% in the >8
weeks and 7.9% for >6 weeks). Interestingly, another study
conducted in South Korea demonstrated a low proportion of
patients receiving delayed chemotherapy for colorectal cancer.[5]
It remains to be determined whether the difference in
chemotherapy delay is derived from ethnic differences or different
medical systems.
This study has several limitations. An important limitation of
our study was the potential selection bias, as this study was
conducted in a single center. Because of the retrospective study
design, deﬁnite inclusion criteria of early chemotherapy initiation
could not be conﬁrmed, and it is difﬁcult to describe how many
patients were not able to receive the intended early chemothera-6py, although earlier chemotherapy was the principal strategy of
speciﬁc surgical oncologists in our hospital. In our study,
different chemotherapeutic agents were used for patients with
stage II–IV cancer. Surgery type and resection extent were diverse
between the groups especially for patients with stage IV cancer.
Nevertheless, our patients with stage IV cancer showed similar
metastasis distributions, and all of them underwent primary
colon resection with similar rates of metastasectomy, which
demonstrates that the surgical burden imposed on patients with
stage IV cancer might be comparable between the 2 groups.
Another concern of early chemotherapy initiation is increasing
hospital stay. Longer hospital stays may increase the incidence of
hospital-acquired infections, although this concern could not be
evaluated using our retrospective data. In our nation’s speciﬁc
socioeconomic status, chemotherapy maintenance during the
hospital stay after surgery was not strongly prohibited because of
the relatively low hospital stay charge. Although we believe that
surgical oncologist-driven chemotherapy might reduce the
interval between surgeon referral and medical oncologist
consultation, the medical oncologist is still in charge of
postoperative chemotherapy in most other academic hospitals
in South Korea. This paradigm of “early chemotherapy strategy”
might not be applicable for patients in different medical systems.
Besides, early chemotherapy initiation strategy wasmainly driven
by speciﬁc surgeons at a single institution that an interdisciplinary
effort by medical and surgical oncologists to plan an early
initiation of chemotherapy was not maintained. This signiﬁcantly
erodes the generalizability. These limitations should be evaluated
in a prospective study design.
Kang et al. Medicine (2019) 98:18 www.md-journal.comIn conclusion, the strategy of initiating chemotherapy for colon
cancer before discharge after surgery is feasible. Implementing an
early chemotherapy initiation strategy might even prevent
unnecessary delays that can in turn decrease OS. However,
our study failed to demonstrate that an early initiation strategy
could translate to better clinical outcomes. One of the main
reasons might be the relatively lower rate of chemotherapy delays
in our group compared to other studies; thus, the positive impact
of this strategy might be neutralized. It should be further
validated whether this strategy has any beneﬁts if used in regions
wherein delays of chemotherapy are more common. Our study
may facilitate further prospective studies of in-hospital early
chemotherapy initiation coordinated between surgeons and
medical oncologists and could be used as an initial experience
of early chemotherapy strategy before launching a randomized
controlled trial.
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